Skip to Content
Merck
  • Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.

Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.

Japanese circulation journal (2000-12-08)
H Sakurai, M Kei, K Matsubara, K Yokouchi, K Hattori, R Ichihashi, Y Hirakawa, H Tsukamoto, Y Saburi
ABSTRACT

Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration of intravenous calcium chloride (CaCl2) immediately resolved her hemodynamic collapse.

MATERIALS
Product Number
Brand
Product Description

USP
Atenolol, United States Pharmacopeia (USP) Reference Standard
Atenolol, European Pharmacopoeia (EP) Reference Standard
Supelco
Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Atenolol, ≥98% (TLC), powder